摘要
目的:了解成都地区2007年1月-11月收集的104株临床分离无重复致病阴沟肠杆菌产超广谱β-内酰胺酶(ES-BLs)的发生率,并分析对比临床常用的22种抗菌药物对产酶菌株的体外抗菌活性。方法:随机收集的临床分离无重复致病阴沟肠杆菌,经双纸片协同实验确定产ESBLs菌株后,采用琼脂平板稀释法测定最低抑菌浓度(MIC)。结果:有35株阴沟肠杆菌产ESBLs,占总菌数的33.65%(35/104);药敏实验表明亚胺培南MIC90为4mg/L,细菌敏感率为100%,明显优于头孢类和青霉素类抗菌素和喹诺酮类抗菌素;除亚胺培南外,产ESBLs阴沟肠杆菌对22种抗生素均表现出一定的耐药性;结论:临床分离阴沟肠杆菌产ESBLs的发生率较高,该菌对多种抗菌素有交叉耐药和多重耐药,为控制产ESBLs阴沟肠杆菌的发展,需做好细菌的常规检验和临床的合理用药。
Objective： Understanding the incidence of 97 clinical isolates pathogenic Enterobacter cloacae ESBL collected in Chengdu region from Jan.07 to Nov.07.And analyse and compare the antibacterial activity in vitro of commonly used 22 kinds of clinical antibiotics against the enzyme production strains. Methods： Randomly collect part clinical pathogenic Enterobacter cloacae separated and use agar dilution to evaluate the Minimum Inhibitory Concentration （MIC） when the double- paper rule tells us it can produce ESBL strains Result： There are 35 Enterobacter cloacae producing ESBLs, accounting33.65percent of the total number （35/104） . Imipeneem＇s MIC90 is 4 mg/L; sensitive rate is 100% . This is significantly better than cephalosporins , penicillins antibiotics and ofloxacin, levofloxacin; Except imipenem, the Enterobacter cloacae of ESBLS production show the different extent resistance to 22 kinds of antibiotics. Conclusions： Incidence of causingESBL is higher than others in Enterobacter cloacae. And there is multiple and cruxes resisteance when it is against various antiblotics. To control the growth of the ESBL- produced Enterobacter cloacae, the conventional testing on bacteria and proper clinical use of drug is indispensable.
出处
《内蒙古中医药》
2008年第10期27-30,共4页
Inner Mongolia Journal of Traditional Chinese Medicine
